Skip to main content
QURE
NASDAQ Life Sciences

uniQure 10-Q: $768.4M Cash to 2030, Q3 Loss $61.2M, May 1 2027 PDUFA

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$22.599
Mkt Cap
$1.656B
52W Low
$8.73
52W High
$51.72
52W Position info
159% above low
Off High info
56% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

QURE has more than doubled off its 52-week low of $8.73.

Summary

uniQure's Q3 10-Q shows a $61.2M net loss and $768.4M in cash funding operations into 2030, alongside a May 1, 2027 PDUFA date and a new risk factor flagging that the 48-month data missed its primary endpoint and was not in the BLA.


Key Events · Earnings and Guidance · QURE

  • Q3 Loss Narrows, Revenue Rises

    Net loss was $61.2 million, or $0.88 per share, versus $80.5 million, or $1.38 per share, a year earlier. Total revenues rose to $5.2 million from $3.7 million on higher HEMGENIX royalties.

  • Cash of $768.4M Funds Operations Into 2030

    Cash, cash equivalents and investment securities totaled $768.4 million at September 30, 2026, up from $622.5 million at December 31, 2025, which management says funds projected operating expenses into 2030 including launch preparation and the confirmatory study.

  • May 1, 2027 PDUFA; AdComm Tentatively Planned

    The FDA accepted the AMT-130 BLA under Accelerated Approval with Priority Review and a May 1, 2027 target action date, and stated it is tentatively planning to convene an advisory committee. The MHRA validated the UK MAA in Q3 2026.

  • 48-Month Primary Endpoint Missed Significance

    At 48 months, cUHDRS showed 44% slowing of progression but did not reach statistical significance (p=0.144); TFC showed 61% slowing (p=0.008). A new risk factor states the 48-month topline results were not part of the BLA or MAA.


Analysis · QURE · Life Sciences

The full Q3 report confirms the company is funded well past the AMT-130 decision: $768.4M in cash and investments at September 30, 2026 versus $622.5M at year-end 2025, with management projecting runway into 2030. That matters because the FDA accepted the BLA under Priority Review with a May 1, 2027 PDUFA date and is tentatively planning an advisory committee, so the company can fund both the launch build-out and the ~200-patient confirmatory study without another raise. The offset is the data: the 48-month cUHDRS endpoint missed statistical significance (44% slowing, p=0.144), and the filing's new risk factor concedes the 48-month results were not part of the BLA or MAA — the agency may weigh them. A securities class action over the same Phase I/II disclosures is also live, with the motion to dismiss due today.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, QURE was trading at $22.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $8.73 to $51.72. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

QURE - Latest Insights

QURE
Nov 04, 2026, 7:10 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $22.44
Real-time Price: $20.30 info
Change: -$2.14 (-10%) info
Market Cap: $1.424B info
QURE
Nov 02, 2026, 7:05 AM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $27.66
Real-time Price: $20.30 info
Change: -$7.36 (-27%) info
Market Cap: $1.424B info
QURE
Sep 29, 2026, 9:26 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $22.00
Real-time Price: $20.30 info
Change: -$1.70 (-8%) info
Market Cap: $1.424B info
QURE
Sep 29, 2026, 9:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $22.20
Real-time Price: $20.30 info
Change: -$1.90 (-9%) info
Market Cap: $1.424B info
QURE
Sep 29, 2026, 7:12 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $11.75
Real-time Price: $20.30 info
Change: +$8.55 (+73%) info
Market Cap: $1.424B info